Heron Therapeutics
HRTXHeron Therapeutics is a commercial-stage biotechnology company that develops and commercializes therapeutic innovations for acute care and oncology patients.
Table of contents
Earnings
Next report
Aug 10, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Heron Therapeutics is a commercial-stage biotechnology company that develops and commercializes therapeutic innovations for acute care and oncology patients. The company leverages its proprietary Biochronomer technology to create extended-release formulations that improve the standard of care for postoperative pain and chemotherapy-induced nausea. Its core value proposition centers on reducing opioid dependency and managing complex side effects associated with surgical procedures and cancer treatments.
Heron differentiates itself through its proprietary Biochronomer drug delivery technology and by securing specific FDA classifications for extended-release and non-opioid designations.
Questions, answered.
- What is Heron Therapeutics's market cap?
- Heron Therapeutics (HRTX) has a market capitalization of $86.9M and trades on NASDAQ.
- Who are Heron Therapeutics's competitors?
- Heron Therapeutics's key competitors include Pacira BioSciences, Inc., Pfizer Inc., Merck & Co., Inc., and others. These companies compete in similar markets and product categories.
- Who does Heron Therapeutics partner with?
- Heron Therapeutics's notable partners include Crosslink Network, Centers for Medicare and Medicaid Services.
- Where is Heron Therapeutics headquartered?
- Heron Therapeutics is headquartered in United States of America and employs approximately 126 people. It has been publicly traded since 1987.